ICIEM 2021 infographic: Rare neurometabolic disorders: A focus on aromatic L-amino acid decarboxylase (AADC) deficiency
This infographic, distributed at the PTC Therapeutics symposium at ICIEM 2021, discusses key signs and symptoms, diagnostic tests, best practice management, and investigational gene therapy treatments in development for AADC deficiency
Learn about the etiology and clinical features of AADC deficiency, and how to differentiate from other neurotransmitter disorders
Understand the core diagnostic tests that should be used to confirm a diagnosis of AADC deficiency
Know what treatment options are currently available for AADC deficiency
Find out about potential investigational gene therapy treatments that are in development
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200021 | March 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.